 EMERYVILLE, Calif., April 15, 2021 GLOBE NEWSWIRE -- XOMA Corporation Nasdaq: XOMA today announced its portfolio of potential future milestone and royalty assets has increased with the addition of three Affimed N.V. Nasdaq: AFMD innate cell engager ICE programs for which XOMA could receive future economics. In 2006, Affimed licensed certain XOMA technologies to further its research and discovery efforts. 